Zhongguancun Science Park

Beijing Zhongguancun Science-Tech Development Co., Ltd. is a publicly traded conglomerate that operates as a significant player in China's pharmaceutical and healthcare industries. The company's primary business is conducted through its subsidiary, Beijing Sihuan Pharmaceutical, which specializes in the research, development, and manufacturing of chemical drugs. Its therapeutic focus includes cardiovascular and cerebrovascular diseases, endocrinology, and gastroenterology, with a portfolio featuring established products like amlodipine besylate and gliquidone. Beyond its pharmaceutical core, the company is involved in technology-related real estate and construction projects within the Zhongguancun high-tech hub. Listed on the Shenzhen Stock Exchange (000931), it serves as an industrial bridge between scientific research and commercial healthcare applications. The company maintains extensive manufacturing facilities that are GMP-certified, supporting its large-scale production requirements for the domestic Chinese market.